tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

OCUP Stock Latest News

Ocuphire Pharma announces APX3330 Phase 2 data presentations at retina meetings
The FlyOcuphire Pharma announces APX3330 Phase 2 data presentations at retina meetings
1M ago
OCUP
Ocuphire Pharma announces FDA acceptance of NDA for Nyxol
The FlyOcuphire Pharma announces FDA acceptance of NDA for Nyxol
1M ago
OCUP
OCUP Tanks as Clinical Data Disappoints
Market NewsOCUP Tanks as Clinical Data Disappoints
2M ago
OCUP
Ocuphire Pharma price target lowered to $20 from $26 at H.C. Wainwright
The FlyOcuphire Pharma price target lowered to $20 from $26 at H.C. Wainwright
2M ago
OCUP
Ocuphire craters 31% after trial evaluating oral APX3330 fails to meet endpoint
The FlyOcuphire craters 31% after trial evaluating oral APX3330 fails to meet endpoint
2M ago
OCUP
Ocuphire Pharma did not meet the primary endpoint in Oral APX3330 trial
The FlyOcuphire Pharma did not meet the primary endpoint in Oral APX3330 trial
2M ago
OCUP
Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
Press ReleasesOcuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
2M ago
OCUP
Ocuphire Pharma enrolls first patient in VEGA-2 Phase 3 trial of Nyxol
The FlyOcuphire Pharma enrolls first patient in VEGA-2 Phase 3 trial of Nyxol
3M ago
OCUP
Analysts See Extravagant Gains for These 2 ‘Strong Buy’ Penny Stocks
Stock Analysis & IdeasAnalysts See Extravagant Gains for These 2 ‘Strong Buy’ Penny Stocks
3M ago
OCUP
RIGL
Ocuphire Pharma submits NDA to FDA for Nyxol
The FlyOcuphire Pharma submits NDA to FDA for Nyxol
4M ago
OCUP
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
Press ReleasesOcuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
4M ago
OCUP
Ocuphire to Present at Five Upcoming Investor/Industry Conferences
Press ReleasesOcuphire to Present at Five Upcoming Investor/Industry Conferences
4M ago
OCUP
Ocuphire Pharma enters exclusive license agreement with FamyGen Life Sciences
The FlyOcuphire Pharma enters exclusive license agreement with FamyGen Life Sciences
5M ago
OCUP
VTRS
Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
Press ReleasesOcuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
5M ago
OCUP
Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
Press ReleasesOcuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
5M ago
OCUP
Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
Press ReleasesOcuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
6M ago
OCUP
Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease
Press ReleasesOcuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease
6M ago
OCUP
Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team
Press ReleasesOcuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team
6M ago
OCUP
Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy
Press ReleasesOcuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy
7M ago
OCUP
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert CenterEtf Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.